Your fact-checks will appear here
The use of intracavernosal stem cell therapy and platelet-rich plasma (PRP) for erectile dysfunction (ED) is not endorsed by major urology guideline bodies due to limited clinical evidence and safety concerns.
Early initiation of penile rehabilitation—either with vacuum erectile devices (VEDs) or chronic/regular phosphodiesterase‑5 inhibitors (PDE5‑Is)—is plausibly associated with better preservation of str...
Phosphodiesterase type 5 inhibitors (PDE5i) — oral drugs such as sildenafil — are the evidence‑based, guideline‑recommended first‑line pharmacologic treatment for most men with erectile dysfunction (E...
Premature ejaculation (PE) and delayed ejaculation (DE) sit at opposite ends of the ejaculatory spectrum, and age reshapes how often they appear, why they appear, and how clinicians classify them: PE ...
Erectile dysfunction (ED) is a common, often treatable medical condition defined by the recurrent inability to achieve or maintain an erection sufficient for satisfactory sexual activity, and it frequ...
Vacuum erection devices (VEDs) are widely described as a generally safe, mechanical option for erectile dysfunction and are explicitly recommended for many men with vascular causes of ED, including he...
Major urology societies uniformly endorse vacuum erection devices (VEDs) as a legitimate, non‑invasive option in the management of erectile dysfunction and as part of penile rehabilitation after radic...
Current guideline-based care treats erectile dysfunction (ED) as a condition requiring both risk‑factor modification and shared decision‑making: lifestyle changes and management of comorbid disease ar...
American and European urology authorities position vacuum erection devices (VEDs) as established, non‑pharmacologic options that must be discussed with men who have erectile dysfunction, but neither s...
Commercial L‑arginine supplements and clinical research overlap but are not identical: randomized trials for vasculogenic erectile dysfunction most commonly test moderate-to-high doses around 1.5–6 g/...
Major urology guideline bodies do not endorse routine clinical use of intracavernosal stem cell therapy or platelet‑rich plasma (PRP) for erectile dysfunction (ED): the American Urological Association...